Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323506 | 0.87 | MAPT (0.40) | TP53L3MBTL1ALDH1A1TSHRPOLB | |
| SCHEMBL20323505 | 0.85 | ALDH1A1 (0.35) | TP53CYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL13752703 | 0.82 | NCF1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL12522316 | 0.82 | TP53 (0.50) | TP53CYP4F2CYP4A11L3MBTL1HTT | |
| SCHEMBL20300385 | 0.81 | ALDH1A1 (0.43) | TP53CYP4F2CYP4A11L3MBTL1HTT | |
| SCHEMBL14414058 | 0.81 | USP2 (0.42) | ALDH1A1TSHR | |
| SCHEMBL7705221 | 0.81 | USP2 (0.42) | ALDH1A1TSHR | |
| SCHEMBL1062380 | 0.81 | — | — | |
| SCHEMBL16127663 | 0.81 | TP53 (0.44) | TP53CYP4F2CYP4A11L3MBTL1HTT | |
| SCHEMBL15387041 | 0.81 | TP53 (0.44) | TP53CYP4F2CYP4A11L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158378-A1 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ORION CORPORATION (FI) | 2024-05-16 | — | — | US | claimed |
| EP-4301749-A1 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | Orion Corporation (FI) | 2024-01-10 | — | — | EP | claimed |
| WO-2022184977-A1 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ORION CORPORATION (FI) | 2022-09-09 | — | — | WO | claimed |
| WO-2025051216-A1 | CYP11A1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳众格生物科技有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119330948-A | CYP11A1 inhibitor and application thereof | 西藏海思科制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119330947-A | CYP11A1 inhibitor and application thereof | 西藏海思科制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20250011285-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2025-01-09 | — | — | US | disclosed |
| WO-2024217531-A1 | CYP11A1 INHIBITORS AND USE THEREOF | 西藏海思科制药有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2024-10-10 | — | — | US | disclosed |
| WO-2024199421-A1 | CYP11A1 INHIBITOR | 山东轩竹医药科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| EP-4430027-A1 | CYP11A1 INHIBITORS | Orion Corporation (FI) | 2024-09-18 | — | — | EP | disclosed |
| WO-2013144097-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012011707-A2 | SUBSTITUTED PYRIDINONE DERIVATIVES AND METHODS FOR MANUFACTURING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2012-01-26 | — | — | WO | disclosed |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (GB) | 2006-03-23 | — | — | US | disclosed |
| CN-1668302-A | Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1531821-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNYL MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006927-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP19A1, CYP11B2 | TP53 923/4885CYP4F2 46/4885CYP4A11 5/4885 |
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | MMP9, MMP2, TIMP3 | TP53 2027/4885CYP4F2 2745/4885CYP4A11 2019/4885 |
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | CYP11B1, CYP4A11, CYP19A1 | TP53 1834/4885CYP4F2 20/4885CYP4A11 2/4885 |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPR55, GPR52 | TP53 3515/4885CYP4F2 178/4885CYP4A11 609/4885 |
| US-20240158378-A1 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | CYP2S1, CYP19A1, CYP4A11 | TP53 541/4885CYP4F2 28/4885CYP4A11 3/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | TP53 2758/4885CYP4F2 2274/4885CYP4A11 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.